Results 191 to 200 of about 459,041 (305)

Antiviral and immune modulatory activities of STING agonists in a mouse model of persistent hepatitis B virus infection. [PDF]

PLoS Pathog
Wang Y, Wu S, Li X, Qiao L, Wang H, Yang G, Yan H, Wang K, Jiang JD, Li Y.   +9 more
europepmc   +1 more source

The Ubiquitin-Proteasome System in Hepatitis B Virus Infection and Hepatocarcinogenesis: Viral Manipulation and Therapeutic Targets. [PDF]

J Microbiol Biotechnol
Han J, Kim KH, Seo SU.
europepmc   +1 more source

Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis. [PDF]

Sci Rep
Yang Y, Xing H, Wu G, Zhao Y.
europepmc   +1 more source

Epidemiological characteristics of hepatitis B virus infection in adult patients before, during and after COVID-19 in China. [PDF]

Virol J
Dang H, Li X, Xu L, Peng X, Hu L, Tang P.   +5 more
europepmc   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, EarlyView.
What's New? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Modeling of hepatitis B virus infection spread in primary human hepatocytes. [PDF]

J Virol
Shi Z, Tsuge M, Collier N, Takeuchi Y, Uchida T, Rutter CM, Teraoka Y, Uprichard SL, Ishida Y, Tateno C, Ozik J, Dahari H, Chayama K.   +12 more
europepmc   +1 more source

Predicting optimal impact interventions in the post‐HPV vaccination world

International Journal of Cancer, EarlyView.
Abstract Prophylactic vaccination is a powerful tool that changes exposure to infections and associated morbidity of preventable diseases. We discuss the impact of pneumococci and human papillomavirus (HPV) vaccination on the population biology of the two micro‐organisms and related public health effects.
Matti Lehtinen, Marc Lipsitch, Ville N. Pimenoff, Karin Sundström, Johannes Berkhof, Iacopo Baussano, Simopekka Vänskä, Joakim Dillner   +7 more
wiley   +1 more source

Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D). [PDF]

Open Forum Infect Dis
Ingiliz P, Quang EV, Ndow G, Lemoine M, Ceesay A, Drammeh S, Hilleret MN, Bordy L, Decaens T, Mazialivoua AL, Shimakava Y, Touray AB, Pawlotsky JM, Chemin I, Chevaliez S, Leroy V.   +15 more
europepmc   +1 more source

Longitudinal changes in health‐related quality of life after a breast cancer diagnosis in sub‐Saharan Africa: Evidence from the prospective ABC‐DO cohort

International Journal of Cancer, EarlyView.
What's New? Breast cancer is now the most common malignancy among women in sub‐Saharan Africa (SSA). Its impact on survivors’ quality of life and Global Health Status (GHS), however, remains inadequately studied in this setting. Here, using data from the African Breast Cancer‐Disparities in Outcomes (ABC‐DO) study, the authors examined GHS over time in
Shamsudeen Mohammed, Moses Galukande, Allen Naamala, Groesbeck Parham, Leeya Pinder, Angelica Anele, Shadrach Awa Offiah, Annelle Zietsman, Joachim Schüz, Valerie McCormack, Isabel dos‐Santos‐Silva   +10 more
wiley   +1 more source

A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions. [PDF]

CPT Pharmacometrics Syst Pharmacol
Boivin-Champeaux C, Schmidt S, Balsitis S, Azeredo FJ, Feigelman JS.   +4 more
europepmc   +1 more source